Abstract:Multiple sclerosis (MS) is a complex autoimmune disease, and several therapies for MS have been developed and widely used. However, existing medications for MS were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for MS prevention are still needed. We performed Mendelian randomization (MR) to explore potential drug targets for MS using summary statistics from the International Multiple Sclerosis Genetics Consortium (NCase = 47,429, NControl = 68,374) and further replicated in UK Biobank (NCase = 1,356, NControl = 395,209) and FinnGen cohorts (NCase = 1,326, NControl = 359,815). Genetic instruments for 734 plasma and 154 cerebrospinal fluid (CSF) proteins were obtained from recently published genome-wide association studies (GWAS). The reverse causality detection using bidirectional MR analysis and Steiger filtering, Bayesian colocalization, and phenotype scanning that searched previously-reported genetic variant-trait associations were implemented to consolidate the MR findings further. In addition, the protein-protein interaction (PPI) network was performed to reveal potential associations among proteins and/ or present MS medications. At Bonferroni significance (P < 5.63×10−5), MR analysis revealed six protein-MS pairs. In plasma, per SD increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratio (OR) for the proteins above were 0.83 (95% confidence interval [CI], 0.79-0.89), 0.59 (95% CI, 0.48-0.71), and 0.88 (95% CI, 0.83-0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42-7.41) increased the risk of MS, while SLAMF7 (OR, 0.42; 95% CI, 0.29-0.60) and CD5L (OR, 0.30; 95%CI, 0.18-0.52) decreased the risk. None of the six above proteins had reverse causality. Bayesian colocalization suggested that FCRL3 (coloc.abf-posterior probability of hypothesis 4 [PPH4] = 0.889), TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930), and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with MS. FCRL3, TYMP, and SLAMF7 interacted with target proteins of current MS medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically-determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1, and SLAMF7 had causal effects on MS risk. These findings suggested those five proteins might be promising drug targets for MS and warrant further clinical investigation, especially FCRL3 and SLAMF7.

Integrated analyses of single-cell transcriptome and Mendelian randomization reveal the protective role of FCRL3 in multiple sclerosis

Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis

Combining gene expression microarrays and Mendelian randomization: exploring key immune-related genes in multiple sclerosis

Four FCRL3 Gene Polymorphisms (FCRL3_3, _5, _6, _8) Confer Susceptibility to Multiple Sclerosis: Results from a Case-Control Study

Integrating Genetic and Proteomic Data to Elucidate the Association Between Immune System and Blood-Brain Barrier Dysfunction with Multiple Sclerosis Risk and Severity

Multi-omics integration prioritizes potential drug targets for multiple sclerosis

Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci

Genetically Predicted Association of 91 Circulating Inflammatory Proteins with Multiple Sclerosis: A Mendelian Randomization Study

Integrative analysis revealed potential causal genetic and epigenetic factors for multiple sclerosis

Functional relevance for multiple sclerosis-associated genetic variants

Genome-wide identification and analysis of the eQTL lncRNAs in multiple sclerosis based on RNA-seq data

Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis

A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis

Identification of drug targets for Sjögren's syndrome: multi-omics Mendelian randomization and colocalization analyses

Causal association between the peripheral immunity and the risk and disease severity of multiple sclerosis

Peripheral mononuclear cells and systemic lupus erythematosus association: Integrated study of single-cell sequencing and mendelian randomization analysis

Mendelian Randomization Analysis of Circulating Cytokines and Risk of Autoimmune Neuroinflammatory Diseases

Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Transcriptome-wide Mendelian Randomization During CD4+ T Cell Activation Reveals Immune-Related Drug Targets for Cardiometabolic Diseases

Brain proteome‐wide association study linking‐genes in multiple sclerosis pathogenesis

Systematic identification of therapeutic targets for coronary artery calcification: an integrated transcriptomic and proteomic Mendelian randomization